Infliximab biosimilar recommended for PBS

The PBAC has recommended the PBS listing of the infliximab biosimilar Inflectra™ for the same indications that apply to its comparator drug Remicade™. It has also recommended Inflectra™ for ‘a’ flagging, meaning pharmacists can substitute biosimilars for brand name original biologics. However as reported by the limbic last month the ‘a’ flagging of biosimilars has ...

Already a member?

Login to keep reading.

© 2021 the limbic